---
pmid: '23665919'
title: Attenuation of insulin signalling contributes to FSN-1-mediated regulation
  of synapse development.
authors:
- Hung WL
- Hwang C
- Gao S
- Liao EH
- Chitturi J
- Wang Y
- Li H
- Stigloher C
- Bessereau JL
- Zhen M
journal: EMBO J
year: '2013'
full_text_available: false
pmcid: PMC3680742
doi: 10.1038/emboj.2013.91
---

# Attenuation of insulin signalling contributes to FSN-1-mediated regulation of synapse development.
**Authors:** Hung WL, Hwang C, Gao S, Liao EH, Chitturi J, Wang Y, Li H, Stigloher C, Bessereau JL, Zhen M
**Journal:** EMBO J (2013)
**DOI:** [10.1038/emboj.2013.91](https://doi.org/10.1038/emboj.2013.91)
**PMC:** [PMC3680742](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680742/)

## Abstract

1. EMBO J. 2013 Jun 12;32(12):1745-60. doi: 10.1038/emboj.2013.91. Epub 2013 May 
10.

Attenuation of insulin signalling contributes to FSN-1-mediated regulation of 
synapse development.

Hung WL(1), Hwang C, Gao S, Liao EH, Chitturi J, Wang Y, Li H, Stigloher C, 
Bessereau JL, Zhen M.

Author information:
(1)Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, 
Canada.

A neuronal F-box protein FSN-1 regulates Caenorhabditis elegans neuromuscular 
junction development by negatively regulating DLK-mediated MAPK signalling. In 
the present study, we show that attenuation of insulin/IGF signalling also 
contributes to FSN-1-dependent synaptic development and function. The aberrant 
synapse morphology and synaptic transmission in fsn-1 mutants are partially and 
specifically rescued by reducing insulin/IGF-signalling activity in postsynaptic 
muscles, as well as by reducing the activity of EGL-3, a prohormone convertase 
that processes agonistic insulin/IGF ligands INS-4 and INS-6, in neurons. FSN-1 
interacts with, and potentiates the ubiquitination of EGL-3 in vitro, and 
reduces the EGL-3 level in vivo. We propose that FSN-1 may negatively regulate 
insulin/IGF signalling, in part, through EGL-3-dependent insulin-like ligand 
processing.

DOI: 10.1038/emboj.2013.91
PMCID: PMC3680742
PMID: 23665919 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare that they have no conflict 
of interest.
